Phase 1bData readout

CRB-913

Obesity

CRBPCorbus Pharmaceuticals

Expected catalystSeptember 30, 2026Company guidance: Sep 30, 2026

Catalyst overview

Event details

Drug or asset: CRB-913
Development stage: Phase 1b
Event type: Data readout
Indication: Obesity

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 1b data readout for CRB-913 in Obesity. The expected timing is based on the latest available company guidance and may change.

Development notes

3/28/25- First patient dosed. 6/30/25- Initiated MAD portion. 8/5/25- SAD portion completed. SAD/MAD data later in 2025. 11/12/25:- On track to complete SAD/MAD and start Ph1b obesity dose-ranging study by end 2025. 12/10/25:- Plan to release Ph1a SAD/MAD results on December 11, 2025; webcast and call scheduled. 03/09/26:- Ph1a SAD/MAD completed; 2.9% 14-day weight loss with favorable GI safety. CANYON-1 Ph1b obesity study completion expected summer 2026. 04/14/26:- CANYON-1 Ph1b obesity trial reached LPFV; completion and data readout expected Summer 2026. 05/12/26:- Enrollment completed in 240-patient CANYON-1 Ph1b obesity trial; 16-week topline data expected Summer 2026. 08/06/26:- CANYON-1 last visit reiterated; topline data expected September 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

What is being tracked?

This catalyst tracks a Phase 1b data readout for CRB-913 in Obesity. The expected timing is based on the latest available company guidance and may change.